Stockscreener 앱 받기
306.16
1.14%
-3.54
전일 마감가:
$309.70
열려 있는:
$316
하루 거래량:
1.28M
Relative Volume:
1.28
시가총액:
$21.63B
수익:
$3.22B
순이익/손실:
$542.70M
주가수익비율:
40.93
EPS:
7.4805
순현금흐름:
$458.00M
1주 성능:
+11.85%
1개월 성능:
+24.83%
6개월 성능:
+2.92%
1년 성능:
+45.38%
1일 변동 폭
$301.46
$316.00
1주일 범위
$271.77
$320.33
52주 변동 폭
$202.79
$322.34
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
306.16 | 21.63B | 3.22B | 542.70M | 458.00M | 7.4805 |
ISRG
Intuitive Surgical Inc
|
482.22 | 170.78B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
152.14 | 43.28B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.76 | 37.85B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.80 | 36.95B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
219.85 | 32.03B | 5.40B | 1.49B | 1.78B | 10.12 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
WST FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 7 Deadline in Securities Class ActionWST - TMX Newsfile
West Pharmaceutical announces up to $1B share repurchase program - MSN
Barclays raises West Pharmaceutical price target on strong demand By Investing.com - Investing.com Nigeria
Research Alert: CFRA Raises Rating On West Pharmaceutical Services, Inc. To Buy From Hold - Moomoo
West Pharmaceutical Services Inc. stock outperforms competitors despite losses on the day - MarketWatch
Barclays raises West Pharmaceutical price target on strong demand - Investing.com
West Pharmaceutical Services Q1 2026: $2.13 EPS Tops Estimates — Deep Dive - AlphaStreet
Stephens Adjusts Price Target on West Pharmaceutical Services to $360 From $320, Maintains Overweight Rating - marketscreener.com
A Quick Look at Today's Ratings for West Pharmaceutical Services(WST.US), With a Forecast Between $285 to $365 - Moomoo
Deutsche Bank Adjusts West Pharmaceutical Services PT to $340 From $315, Maintains Buy Rating - marketscreener.com
Jefferies Adjusts West Pharmaceutical Services Price Target to $365 From $295, Maintains Buy Rating - marketscreener.com
Citigroup Adjusts West Pharmaceutical Services PT to $400 From $375, Maintains Buy Rating - marketscreener.com
Evercore ISI Adjusts West Pharmaceutical Services PT to $390 From $320, Maintains Outperform Rating - marketscreener.com
TD Cowen Adjusts West Pharmaceutical Services PT to $365 From $350, Maintains Buy Rating - marketscreener.com
West Pharmaceutical: A High-Quality Beat-And-Raise With More Upside Ahead - Seeking Alpha
West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2026 Earnings Call Transcript - Insider Monkey
West Pharmaceutical Services Q1 Earnings Call Highlights - MarketBeat
West Pharmaceutical Services Inc (WST) Q1 2026 Earnings Call Hig - GuruFocus
West Pharma jumps as packaging components drive strong Q1 beat - MSN
WST Q1 Deep Dive: High-Value Components and Operational Execution Drive Outperformance - TradingView
West Pharmaceutical Q1 2026 slides: 47% EPS surge on biologics boom - Investing.com Australia
West Pharmaceutical: Q1 Earnings Snapshot - theheraldreview.com
West Pharma lifts 2026 profit forecast on strong demand for medical equipment - 1470 & 100.3 WMBD
West Pharmaceutical Lifts Outlook After Powerful Q1 - TipRanks
A Look at West Pharmaceutical Services Inc (WST) After 12.9% Gai - GuruFocus
BofA raises West Pharmaceutical stock price target on strong quarter By Investing.com - Investing.com Canada
TD Cowen raises West Pharmaceutical stock price target on guidance By Investing.com - Investing.com Australia
West Pharma sees plastics, elastomer demand surge with GLP-1 growth - Rubber News
[10-Q] WEST PHARMACEUTICAL SERVICES INC Quarterly Earnings Report - Stock Titan
WST Stock Climbs As Dublin Expansion Targets GLP‑1 Drug Wave - StocksToTrade
WST Stock Climbs As Dublin Expansion Targets GLP-1 Drug Boom - timothysykes.com
West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1 - Benzinga
West Pharmaceutical Services, Inc. Raises Earnings Guidance for the Full Year 2026 - marketscreener.com
West Pharmaceutical Services Q1 2026 Earnings Call Transcript - MarketBeat
Evercore ISI raises West Pharmaceutical price target on strong results By Investing.com - Investing.com Canada
West Pharmaceutical Services, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
West Pharmaceutical Stock Is Soaring After Earnings. It’s a Sneaky GLP-1 Play. - Barron's
WST Stock Jumps on Q1 Earnings & Sales Beat, EPS View Up on HVP Growth - TradingView
WST Stock Climbs As Dublin Expansion Targets GLP‑1 Drug Boom - StocksToTrade
West Pharmaceutical Services (NYSE:WST) Posts Earnings Results, Beats Expectations By $0.45 EPS - MarketBeat
West Pharmaceutical Services Reports Strong Q1 2026 Results Driven by Double-Digit Organic Net Sales Growth - Minichart
West Pharmaceutical (WST) jumps on Q1 beat and raised 2026 outlook - Quiver Quantitative
West Pharmaceutical Services Stock Climbs As Dublin Expansion Targets Obesity Drug Boom - timothysykes.com
West Pharmaceutical Services (NYSE:WST) Shares Gap Up on Earnings Beat - MarketBeat
West Pharmaceutical Services Crushes Q1 2026 Profit Estimates by 26.0% - AlphaStreet
West Pharmaceutical Q1 2026 slides: 47% EPS surge on biologics boom By Investing.com - Investing.com South Africa
West Pharma Sees FY EPS $8.15-EPS $8.50 >WST - Moomoo
West Pharmaceutical Services CEO Eric Green plans to retire after successor is named - MSN
Compared to Estimates, West Pharmaceutical (WST) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: West Pharmaceutical Services Q1 2026 beats expectations - Investing.com Canada
West Pharmaceutical Services, Inc. Provides Earnings Guidance for the Second Quarter 2026 - marketscreener.com
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
0.15%
자본화:
|
볼륨(24시간):